Amgen Inc. (AMGN)
NASDAQ: AMGNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AMGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $235.64B
- P/E (TTM)
- 25.25
- Forward P/E
- 17.34
- EPS (TTM)
- $17.25
- Dividend yield
- 2.28% ($9.94)
- Ex-dividend date
- Nov 20, 2026
- 52-week range
- 312.39 – 483.99
- Day range
- 434.51 – 445.49
- Volume / Avg
- 4.94M / 2.82M
- Beta
- —
- Shares outstanding
- 540.91M
52-week range
AMGN stock today
Amgen (AMGN) closed at $435.64 on Nov 20, down 0.15% (-$0.66), versus the S&P 500's 3.70% decline. Shares are 10.0% below their 52-week high of $483.99, set on Nov 5, 2026 and 39.5% above the 52-week low of $312.39, in the middle of the past year's range. AMGN is up 33.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 29.1%.
At 25.3x trailing earnings, Amgen trades in line with the peer-group median of 27.2x. Its forward P/E of 17.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Amgen pays an annual dividend of $9.94 per share, a 2.28% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Amgen
Company profileAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Robert A. Bradway
- Headquarters
- Thousand Oaks, CA
- Employees
- 31,500
- IPO year
- 1983
- Website
- amgen.com
Financial highlights
Full financialsIn fiscal 2025, Amgen generated $36.75 billion in revenue, up 10.0% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $7.71 billion (+88.5% year over year), for a net margin of 21.0% versus a median of 23.8% in the prior 5 years. Gross margin was 67.2% (up from 61.5%) and operating margin 24.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B |
| Growth | +9.95% | +18.57% | +7.09% | +1.32% | +2.18% |
| Net income | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B |
| EPS (diluted) | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
Analyst forecast
ForecastConsensus (34 analysts)
hold
Avg. price target
$431.81-0.88%
- Strong buy 4
- Buy 7
- Hold 18
- Sell 3
- Strong sell 2
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $5.64 vs $5.74
- Surprise
- -1.74%
Dividends
Dividend history- Annual dividend
- $9.94
- Dividend yield
- 2.28%
- Last payment
- $2.52
- Ex-dividend date
- Nov 20, 2026
- Pay date
- Dec 11, 2026
AMGN news
All AMGN news- Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to KnowNasdaq
- Noteworthy ETF Inflows: TQQQ, SPCX, NFLX, AMGNNasdaqTQQQ, NFLX, AMGN
- ProKidney Names Farah Ali CMO As Phase 3 Kidney Therapy Trial AdvancesNasdaqABBV, AMGN, IMVT, PROK
- Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market WeaknessInvestor's Business Daily
- AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug KlygefaNasdaqAZN, JNJ, AMGN, ARGX
- Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?NasdaqREGN, SNY, BIIB, VRTX
- Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?NasdaqAMGN, VRTX
- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike DealsNasdaqAMGN, ARGX, AZN, BEAM
Amgen peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GILDGilead Sciences Inc. | 166.43 | -0.06% | $206.43B | vs AMGN |
| MRNAModerna Inc. | 195.00 | -2.17% | $78.90B | vs AMGN |
| ARGXargenx SE ADR | 925.70 | -1.73% | $58.21B | vs AMGN |
| BIIBBiogen Inc. | 249.59 | +1.00% | $36.89B | vs AMGN |
| RVMDRevolution Medicines Inc. | 161.20 | +1.11% | $34.87B | vs AMGN |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs AMGN |
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs AMGN |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs AMGN |
Indexes, lists and sector
Index membership
Appears in lists
Amgen stock FAQ
What is Amgen's stock price today?
AMGN last traded at $435.64 as of Nov 20, 4:00 PM EST, down 0.15% on the day. Prices are delayed at least 15 minutes.
Does Amgen pay a dividend?
Yes. Amgen pays $9.94 per share annually, a 2.28% yield. The most recent dividend of $2.52 had an ex-dividend date of Nov 20, 2026.
What is AMGN's P/E ratio?
AMGN trades at a trailing P/E ratio of 25.25 and a forward P/E of 17.34, compared with a median of 27.2 for its closest peers.
Is Amgen in the S&P 500?
Yes. Amgen (AMGN) is a constituent of the S&P 500 index.
Who is Amgen's CEO?
Mr. Robert A. Bradway is the chief executive officer of Amgen Inc., which has about 31,500 employees.
Has AMGN ever split its stock?
Yes. The most recent AMGN stock split was a 2-for-1 split on Nov 22, 1999, one of 5 splits on record.
What is the AMGN 52-week high?
The 52-week high for AMGN is $483.99 and the 52-week low is $312.39. The stock is currently 10.0% below its high.